CD63 and ovarian cancer: The clinical potential of nPLEX emerged from its high-level integration and multiplexing capacity as the label-free detection of ovarian cancer-derived EpCAM (+) and CD24 (+) relative to CD63(+) exosomes in ascites fluids [110].